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We read with great interest the letter by Dominguez-Rodriguez, Abreu-Gonzalez and 
Reiter regarding our article.[1] We thank the authors for pointing out that although the 
circadian “clock” genes are expressed by most tissues, the suprachiasmatic nuclei of 
the hypothalamus are predominantly responsible for their secretion and regulation in 
mammals and they also influence the expression of melatonin. Melatonin has numerous 
benefits as described in their letter but it is secreted in a circadian pattern. This may 
partly explain our findings of a circadian variation of myocardial infarction size, 
depending on the time of onset of symptoms. We admire their enthusiasm to champion 
melatonin as a promising cardioprotective agent against ischemia – reperfusion injury 
in the setting of ST-segment elevation myocardial infarction (STEMI).[2] Although the 
MARIA trial[2] was neutral for infarct size reduction, a post-hoc analysis found that 
those presenting within 2.5 hours of symptoms onset showed a significant reduction in 
myocardial infarct size.[3] This highlights the fact that careful patient selection is 
crucial to optimize the translation of promising cardioprotective therapies in the clinical 
setting.[4] Furthermore, around 50% of STEMI patients treated by primary 
percutaneous coronary intervention develop microvascular obstruction[5] and therefore 
any cardioprotective therapy, even if administered via the intra-coronary route, would 
fail to reach the microcirculation in half of these patients. An alternative approach, 
which has not yet been studied so far, may be to combine low dose thrombolysis (to 
regain flow in the microcirculation as currently being investigated in the T-TIME trial 
- NCT02257294) with a promising cardioprotective therapy (to reach the ischemic 
myocytes and protect against lethal myocardial injury), in order to minimize 
reperfusion injury and improve outcomes in these patients.  
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